REHOVOT, Israel and BRIDGEWATER, N.J., July 25, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce second quarter ended June 30, 2016 financial results and host a conference call and webcast on Wednesday, August 10.
Conference Call & Webcast
Wednesday, August 10, 2016 @ 8:30am Eastern Time
Replays, through August 24th:
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, now in Phase III, FMX 103 for the treatment of rosacea now in Phase II, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.